Assess whether a CMO finding is a delay or a refuse-to-file risk (74f8ee)

Situation

In a 505(b)(2) program relying on literature plus a bridging study, CMC comparability package for a site change is the evidence after a site-change that invalidates stability claims. Labeling negotiator has to pick A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences CMC and Development Pathways close using CMC comparability package for a site change.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose A CMO finding is a delay / A refuse-to-file risk using CMC comparability package for a site change after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize A CMO finding is a delay now; CMC comparability package for a site change already has the discriminator after a site-change that invalidates stability claims.
• Keep A refuse-to-file risk in force until CMC comparability package for a site change is completed after a site-change that invalidates stability claims for labeling negotiator.
• Treat CMC comparability package for a site change as A CMO finding is a delay because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page a CMO finding is turns on in CMC comparability package for a site change.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether CMC comparability package for a site change supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a site-change that invalidates stability claims and write the one fact that would move a CMO finding is for labeling negotiator.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.